Farnos Camille, Barbier Vincent, Doussiere Marie, Deprez Valentine, Hamidou Yannis, Bruy Pierre Antoine, Sobhy Danial Jean Marc, Goeb Vincent
Department of Rheumatology, Amiens University Hospital, 80054 Amiens, France.
Department of Physical Medicine and Rehabilitation, Victor Pauchet Amiens Clinic, 80090 Amiens, France.
J Clin Med. 2024 Aug 7;13(16):4608. doi: 10.3390/jcm13164608.
Janus kinase inhibitors (JAKis) belong to a new class of targeted oral drugs that have been added to the therapeutic arsenal for rheumatoid arthritis (RA). The aim of this study was to evaluate the efficacy and safety profiles of these four available molecules (tofacitinib, baricitinib, filgotinib, and upadacitinib) in real life. A retrospective, single-center observational study including all patients treated with JAKis for RA from 1 October 2017 to 1 December 2023. We assessed the maintenance rate at 24 months, which is an indirect reflection of the clinical and biological safety and efficacy profiles. The 76 patients in our study were thus treated for the first time with anti-JAK, including 55 patients with baricitinib (BAR), 9 patients with tofacitinib (TOF), 4 patients with upadacitinib (UPA), and 8 patients with filgotinib (FIL). The majority of our patients had BAR introduced as the first intention. The therapeutic maintenance at 2 years for all our patients was 50%. The average maintenance duration was 8.6 months and was similar in all the groups. Of the 76 patients included in this study treated with Baricitinib (72.3%), 38 (50%) discontinued their treatment after two years of follow-up. Although this retrospective study is subject to various biases, it shows that the persistence rates of the four JAKi molecules in daily practice did not differ significantly, thus confirming the long-term efficacy of these drugs.
Janus激酶抑制剂（JAKis）属于一类新型的靶向口服药物，已被纳入类风湿性关节炎（RA）的治疗药物库。本研究的目的是评估这四种可用分子（托法替布、巴瑞替尼、非戈替尼和乌帕替尼）在实际应用中的疗效和安全性。这是一项回顾性、单中心观察性研究，纳入了2017年10月1日至2023年12月1日期间所有接受JAKis治疗RA的患者。我们评估了24个月时的维持率，这是临床和生物学安全性及疗效的间接反映。我们研究中的76例患者首次接受抗JAK治疗，其中55例使用巴瑞替尼（BAR），9例使用托法替布（TOF），4例使用乌帕替尼（UPA），8例使用非戈替尼（FIL）。我们的大多数患者最初使用的是BAR。我们所有患者的两年治疗维持率为50%。平均维持时间为8.6个月，在所有组中相似。在本研究纳入的76例接受巴瑞替尼治疗的患者中（72.3%），38例（50%）在随访两年后停止治疗。尽管这项回顾性研究存在各种偏差，但它表明这四种JAKi分子在日常实践中的持续使用率没有显著差异，从而证实了这些药物的长期疗效。
